Get the Stockscreener App
29.62
0.93%
-0.59
Neurogene Inc stock is traded at $29.62, with a volume of 9,256.
It is down -0.93% in the last 24 hours and up +57.53% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$30.21
Open:
$29.73
24h Volume:
9,256
Relative Volume:
0.06
Market Cap:
$423.95M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+29.62%
1M Performance:
+57.53%
6M Performance:
+172.09%
1Y Performance:
-39.45%
1-Day Range:
$29.01
$30.52
1-Week Range:
$22.02
$32.55
52-Week Range:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
29.70 | 431.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.58 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.01 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
544.91 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
325.17 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Does Neurogene Inc. qualify in momentum factor screeningProduct Launch & Reliable Price Action Trade Plans - newser.com
How to track smart money flows in Neurogene Inc.2025 Macro Impact & Low Drawdown Investment Strategies - newser.com
Why Neurogene Inc. stock remains a top recommendationQuarterly Market Summary & Verified Swing Trading Watchlist - newser.com
Neurogene’s (NGNE) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Neurogene (NASDAQ:NGNE) - MarketBeat
Neurogene (NASDAQ:NGNE) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
How Neurogene Inc. (UU8) stock responds to job market shiftsJuly 2025 Sector Moves & High Win Rate Trade Tips - newser.com
HC Wainwright & Co. Reiterates Neurogene (NGNE) Buy Recommendation - Nasdaq
Neurogene Reaches Accord With FDA on Plan for Registrational Trial for Rett Syndrome Gene Therapy NGN-401 - CGTLive®
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Fourth Quarter of 2025 - MarketScreener
Neurogene to begin Rett syndrome gene therapy registrational trial in Q4 - Investing.com Nigeria
Real time pattern detection on Neurogene Inc. stockQuarterly Trade Summary & Advanced Swing Trade Entry Alerts - newser.com
Neurogene Completes FDA Talks for Rett Syndrome Trial - TipRanks
Neurogene : Poster ESGCT2025 RoA Final Print - MarketScreener
23 developmental milestones — Neurogene to start Embolden dosing in Q4 2025 after FDA talks and ICV data - Stock Titan
What recovery options are there for Neurogene Inc.2025 Top Gainers & Low Risk Entry Point Guides - newser.com
Forecasting Neurogene Inc. price range with options dataTrade Exit Summary & Real-Time Stock Entry Alerts - newser.com
What drives Neurogene Inc UU8 stock priceBollinger Bands Signals & Free Explosive Wealth Accumulation - earlytimes.in
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - Stock Titan
What analysts say about Neurogene Inc stockInflation Impact on Stocks & Big Data Market Reports - earlytimes.in
Short interest data insights for Neurogene Inc.July 2025 Highlights & Entry Point Confirmation Signals - newser.com
Is Neurogene Inc a good long term investmentWeekly Market Snapshot & Free Rapid Profit Acceleration - earlytimes.in
Neurogene Insiders Placed Bullish Bets Worth US$1.46m - simplywall.st
Strategies to average down on Neurogene Inc.Portfolio Performance Summary & Free Fast Gain Swing Trade Alerts - newser.com
Long term hold vs stop loss in Neurogene Inc.2025 Year in Review & Momentum Based Trading Ideas - newser.com
Neurogene announces inducement grants under Nasdaq Listing Rule - MarketScreener
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
We're Not Very Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Rate - 富途牛牛
Developing predictive dashboards with Neurogene Inc. dataQuarterly Market Review & Weekly Return Optimization Plans - newser.com
Does Neurogene Inc. stock trade at a discount to peersJuly 2025 Patterns & Free Community Consensus Stock Picks - newser.com
Is Neurogene Inc. trending in predictive chart modelsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright - TipRanks
Batten Disease Pipeline 2025: Innovative Clinical Developments by 10+ Global Leaders – DelveInsight | Featuring Polaryx Therapeutics, Neurogene, Theranexus, M6P Therapeutics, Regenxbio - The Globe and Mail
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):